<DOC>
	<DOC>NCT02336594</DOC>
	<brief_summary>This is a Phase 1, randomized, open-label, 4-way crossover pharmacokinetic (PK) and pharmacodynamic (PD) study in healthy adult male subjects designed to assess the relative bioavailability of RDEA3170 2.5 mg tablets administered as a 10 mg dose (2.5 mg × 4 tablets) and of a single RDEA3170 10 mg tablet. This study will also assess the effect of a low-fat and high-fat meal on the PK and PD of RDEA3170 10 mg tablets.</brief_summary>
	<brief_title>RDEA3170 Bioavailability Study</brief_title>
	<detailed_description />
	<criteria>Subject is able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first studyrelated activity Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2 Subject has a Screening serum urate level ≤ 7 mg/dL Subject is free of any clinically significant disease or medical condition, per the Investigator's judgment Subject has a history or suspicion of kidney stones Subject has undergone major surgery within 3 months prior to Screening Subject donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1 Subject has inadequate venous access or unsuitable veins for repeated venipuncture Subject has a Screening serum creatinine value above the upper limit of normal during Screening or at Day 2 (Admission) Subject cannot swallow multiple tablets Subject is a heavy caffeine drinker Subject is unwilling to comply with the dietary restrictions of the study Subject is unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the Investigator, may interfere with participation in the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>